A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

By F. Nevens, P. Andreone, G. Mazzella, S. Strasser, C. Bowlus, P. Invernizzi, J. Drenth, P. Pockros, J. Reguła, U. Beuers and 22 more. New England Journal of Medicine, 2016

957 citations recorded by the source corpus.

Subfields: Hepatology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/c7ea5898e6a585db3c4aa4257964060b4fd55605

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. Natascha Roehlen
2. E. Crouchet
3. T. Baumert

Citations in the corpus

• Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives (2020, background): “Recent clinical studies further indicate improvement of histological features, including fibrosis in patients with PBC after long-terms OCA treatment [305].”
• Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2018, background): “After 1 year, this primary endpoint was met by 46% of patients in the titration group, 47% in the 10 mg/day group, and 10% of patients in the placebo group.(161) Improvements in other liver chemistries and inflammatory markers were also noted in OCA-treated patients.”
• EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017, neutral): “Treatment with OCA is associated with a dose dependent exacerbation inpruritus, leading to treatmentdiscontinuation in1–10% of patients [130,131].”